Post hoc analysis of 271 BLISS-LN patients with class III/IV (±V) lupus nephritis on mycophenolate mofetil: belimumab vs placebo gave a 14.9% complete renal response difference (10.3% in the overall trial), with fewer serious adverse events.
Secondary analysisn = 271
Furie et al. A post hoc analysis of BLISS-LN found Belimumab plus mycophenolate mofetil improves kidney outcomes versus placebo plus mycophenolate mofetil in active lupus nephritis